These structural changes reduce lapatinib’s binding ability, making it less effective in inhibiting HER2 phosphorylation and downstream signaling, thereby promoting tumor cell proliferation and survival (Mariana et al., 2013). The gene discussed is ERBB2; the disease is neoplasm.